Visceral abdominal-fat accumulation associated with use of indinavir

Lancet

Volumn 351, Issue 9106, 1998, Pages 871-875

  Miller, Kirk D ^a,d   Jones, Elizabeth ^a   Yanovski, Jack A ^b   Shankar, Rani ^a   Feuerstein, Irwin ^a   Falloon, Judith ^c  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; PROTEINASE INHIBITOR;

ABDOMEN; ADIPOSE TISSUE; ADULT; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID STORAGE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; UMBILICUS; VISCERA;

EID: 0032554552     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)11518-5     Document Type: Article

References (25)

1. 1 Bartlett JG. Protease inhibitors for HIV infection. Ann Intern Med 1996; 124: 1086-88.
2. 2 Corey L, Holmes KK. Therapy for human immunodeficiency virus infection - what have we learned? N Engl J Med 1996; 335: 1142-43.
3. 3 Deeks SG, Holodniy M, Kahn JO. HIV-1 protease inhibitors: a review for clinicians. JAMA 1997; 277: 145-53.
4. 4 Anon. Drugs for HIV infection. Med Lett Drugs Ther 1997; 39: 111-16.
5. 5 Van Loan MD. Body fat distribution from subcutaneous to intraabdominal: a perspective [editorial]. Am J Clin Nutr 1996; 64: 787-88.
6. 6 Pi-Sunyer. Medical hazards of obesity. Ann Intern Med 1993; 119: 655-60.
7. 7 Matsuzawa Y, Nakamura T, Shimomura I, Kotani K. Visceral fat accumulation and cardiovascular disease. Obesity Res 1995; 3 (suppl 5): 645-47.
8. 8 Borkan GA, Gerzof SG, Robbins AH, Hults DE, Silbert CK, Silbert JE. Assessment of abdominal fat content by computed tomography. Am J Clin Nutr 1982; 36: 172-77.
9. 9 Grauer W, Moss A, Cann C, Goldberg H. Quantification of body fat distribution in the abdomen using computed tomography. Am J Clin Nutr 1984; 39: 631-37.
10. 10 Enzi G, Gaspara M, Biondetti PR, Fiore D, Semisa M, Zurlo F. Subcutaneous and visceral fat distribution according to sex, age, and overweight, evaluated by computed tomography. Am J Clin Nutr 1986; 44: 739-46.
11. 11 Baumgartner RN, Heymsfield SB, Roche AF, Bernardino M. Abdominal composition quantified by computed tomography. Am J Clin Nutr 1988; 48: 936-45.
12. 12 Vehmas T, Kaeremo KJA, Taavitsainen MJ. Measuring visceral adipose tissue content from contrast enhanced computed tomography. Int J Obesity 1996; 20: 570-73.
13. 13 Dixon, AK. Abdominal fat assessed by computed tomography: sex difference in distribution. Clin Radiol 1983; 14: 189-91.
14. 14 Weits T, van der Beek T, Wedel M, ter haar Romeny BM. Computer tomography measurement of abdominal fat deposition in relation to anthropometry. Int J Obesity 1988; 12: 217-25.
15. 15 van der Kooy K, Seidell JC. Techniques for the measurement of visceral fat: a practical guide. Int J Obesity 1993; 17: 187-96.
16. 16 James JS. Protease inhibitor's metabolic side effects: cholesterol, triglycerides, blood sugar, and "crixbelly". In: AIDS Treatment News 1997; issue 277, Aug 15.
17. 17 Fujioka S, Matsuzawa Y, Tokunaga K, Tarui S. Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 1987; 36: 54-59.
18. 18 Wajchenberg BL, Bosco A, Marone MM, et al. Estimation of body fat and lean tissue distribution by dual energy x-ray absorptiometry and abdominal body fat evaluation by computed tomography in Cushing's disease. J Clin Endocr Metab 1995; 80: 2791-94.
19. 19 Macor C, Ruggeri A, Mazzonetto P, Federspil G, Cobelli C, Vettor R. Visceral adipose tissue impairs insulin secretion and insulin sensitivity but not energy expenditure in obesity. Metabolism 1997; 46: 123-29.
20. 20 Matsuzawa Y, Shimomura I, Nakamura T, Keno Y, Kotani K, Tounaga K. Pathophysiology and pathogenesis of visceral fat obesity. Obesity Res 1995; 3 (suppl 2): 187-94.
21. 21 Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. Buffalo hump in HIV-infected patients on antiretroviral therapy [abstr]. 5th Conference on Retroviruses and Oportunistic Infections, 1998: 409.
22. 22 Ruane PJ. Atypical accumulation of fatty tissue [abstr]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy 1997: 1-185.
23. 23 Hengel RL, Watts NB, Lennox JL. Benign symmetric lipomatosis associated with protease inhibitors. Lancet 1997; 350: 1596.
24. 24 Herry I, Bernard L, de Truchis P, Perronne C. Hypertrophy of the breasts in a patient treated with indinavir. Clin Infect Dis 1997; 25: 937-38.
25. 25 Carr A, Samaras K, Burton S, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia, and insulin resistance due to HIV protease inhibitors [abstr]. 5th Conference on Retroviruses and Opportunistic Infections, 1998: 410.